Phase III safety key to Isis antisense CV potential
This article was originally published in Scrip
Executive Summary
Isis Pharmaceuticals’ Phase I data for its cardiovascular antisense therapy suggesting large reductions in apoC-III and triglycerides levels may bode well for the Phase II results expected in mid-2013. But maintaining positive efficacy signals in the Phase III studies without restrictive side-effects may be more difficult.